China SFDA vs NMPA: Understanding China’s Medical Device Regulatory Evolution
In 2018, China replaced the China Food and Drug Administration (国家食品药品监督管理总局, CFDA/SFDA, guójiā shípǐn yàopǐn jiāndū guǎnlǐ zǒngjú) with the National Medical Products Administration (国家药品监督管理局, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú), restructuring oversight of over 14,000 active medical device registrations. This transition redefined device classification, streamlined registration timelines by up to 30%, and introduced stricter post-market surveillance for both domestic and foreign manufacturers.
The change was not cosmetic. While SFDA (often used interchangeably with CFDA in older documentation) operated under a food-and-drug framework, NMPA was created as a dedicated medical products regulator with pharmaceutical, device, and cosmetic oversight separated from food safety. For foreign executives planning China market entry, understanding this evolution is critical — regulatory history determines how legacy registrations are treated, what clinical evidence is accepted, and which pathways remain open for new approvals.
Below, we break down the structural shifts, key differences across registration and classification, and provide a decision framework for navigating both legacy and current requirements.
The Structural Shift: From SFDA to NMPA
China’s medical device regulatory architecture has undergone three distinct phases. The State Food and Drug Administration (SFDA) was first established in 2003, consolidating drug and device oversight under one agency. In 2013, SFDA was renamed to the China Food and Drug Administration (CFDA) with an expanded mandate, but the core regulatory framework remained largely unchanged. The most transformative change came in March 2018, when the National People’s Congress dissolved CFDA and created the NMPA as an agency directly under the newly formed State Administration for Market Regulation (SAMR).
This restructuring separated food safety — moved to the newly created National Health Commission and SAMR’s food safety division — from medical products regulation. NMPA inherited all medical device functions but with a clearer focus on innovation acceleration, international harmonization, and risk-based oversight. The agency also gained authority over drug clinical trial management, cosmetics, and traditional Chinese medicine, while medical device registration remained its largest workload area by volume.
The practical impact for foreign manufacturers: NMPA introduced the Medical Device Registration Certificate (医疗器械注册证, yīliáo qìxiè zhùcè zhèng) with a unified five-year validity period, replacing the previous four-to-five-year patchwork. It also mandated the China Compulsory Certification (CCC) mark integration for certain devices and pushed for adoption of International Medical Device Regulators Forum (IMDRF) standards, reducing redundant local testing requirements in select categories.
Key Regulatory Differences: SFDA vs NMPA
The differences between the SFDA/CFDA era and the current NMPA regime span classification logic, registration timelines, clinical trial expectations, and post-market vigilance. The following table summarizes the most impactful changes for foreign manufacturers.
| Regulatory Dimension | SFDA/CFDA Era (pre-2018) | NMPA Era (post-2018) | Impact on Foreign Manufacturers |
|---|---|---|---|
| Classification System | Three classes (I, II, III) based on risk, but implementation varied by province | Same three classes, but unified national classification catalog with 2,069 device categories | Class I registration now averages 30 working days; Class II averages 60 working days |
| Registration Timeline (Class II) | 80–120 working days typical; technical review often took 6+ months | 60 working days target; technical review capped at 90 working days | 30% reduction in time-to-market for most Class II devices |
| Clinical Trial Requirements | Mandatory clinical trials for most Class II and all Class III devices; limited exemption catalog | Expanded exemption catalog covering 1,200+ device types; clinical evaluation reports accepted for many Class II devices | Reduced trial costs by 40–60% for eligible devices |
| Registration Validity | 4 years (device); 5 years (drug) | 5 years unified for all medical devices | Longer renewal cycles; simplified renewal process with no re-review for unchanged devices |
| Post-Market Surveillance | Adverse event reporting required, but enforcement was inconsistent | Mandatory adverse event reporting, annual summaries, and risk-based inspection frequency | Non-compliance penalties: warnings to 3-year ban on new registrations |
| Quality Management System | GMP certification required; audits by local FDAs every 2–3 years | GMP aligned with ISO 13485; unannounced audits possible; virtual audit options for foreign sites | Cross-recognition with MDSAP reduces duplicate audits |
The most cited improvement among foreign manufacturers is the expanded clinical trial exemption catalog. Under SFDA, roughly 300 device types were exempt from clinical trials; under NMPA, that number has grown to over 1,200. However, if a device falls outside the exemption catalog, NMPA now requires a full Clinical Evaluation Report (CER) following IMDRF guidelines, which raises the documentation bar for novel Class III devices.
Classification and Registration: Before vs After
Device classification under both SFDA and NMPA uses the same three-tier risk structure: Class I (low risk, general controls), Class II (moderate risk, special controls), and Class III (high risk, premarket approval). However, the classification catalog itself has been rewritten.
SFDA’s catalog, last updated in 2014, contained approximately 1,200 device categories with significant overlap and ambiguity — particularly for combination products and software. NMPA released a revised classification catalog in 2021 (effective 2022) that expanded to 2,069 categories, added explicit software classifications, and introduced a dynamic review mechanism allowing reclassification every two years.
For foreign manufacturers, this means a device classified as Class II under the SFDA catalog might now be Class III under NMPA — or vice versa. A real example: standalone diagnostic software for radiology was often Class II under SFDA; under NMPA, it is now explicitly Class III if it provides diagnostic decision support. The cost of misclassification: filing under the wrong class triggers application rejection and a 6-month cooling period before refiling.
Registration procedures also diverged significantly. Under SFDA, foreign manufacturers submitted registration dossiers through a local Chinese agent, and technical review involved significant back-and-forth with little standardization. NMPA introduced an electronic submission portal (e-Registration), standardized dossier templates aligned with IMDRF Table of Contents, and mandated that all foreign applications include a copy of the Free Sale Certificate from the country of origin plus a notarized Chinese translation.
Clinical Trial and Quality Management Changes
Clinical trial requirements represent the single highest-cost variable in China device registration. Under SFDA, most Class II and all Class III devices required a China-specific clinical trial, even if the device was already approved in the US or EU. The cost of a multi-site China trial for a Class III device typically ranged from RMB 3 million to RMB 10 million, with an average timeline of 12–18 months.
NMPA changed this dramatically by adopting the IMDRF framework for clinical evaluation. Manufacturers can now submit a Clinical Evaluation Report (CER) that leverages overseas clinical data, provided the data meets NMPA’s standards for patient population comparability, endpoint alignment, and Good Clinical Practice (GCP) compliance. For devices with an established safety record in the US or EU, NMPA may accept the CER in lieu of a full China trial, reducing costs by 40–60% and saving 6–12 months.
Quality management system (QMS) requirements also evolved. SFDA required manufacturers to hold a valid GMP certificate and undergo periodic on-site audits by provincial FDA offices. NMPA aligned its GMP requirements with ISO 13485:2016 and introduced a risk-based audit frequency — high-risk devices face audits every 2 years, medium-risk every 3 years, and low-risk every 4 years. For foreign manufacturers, NMPA also accepts MDSAP (Medical Device Single Audit Program) audit reports in lieu of separate NMPA GMP audits, a significant time-saver for companies already certified under MDSAP.
Decision Framework: SFDA Legacy vs NMPA Current
For foreign executives deciding how to handle regulatory submissions, the choice is less about SFDA vs NMPA as concurrent options and more about whether your device falls under legacy grandfathering provisions or must follow the current NMPA pathway.
If your device holds a valid registration certificate issued under the SFDA/CFDA regime that expired before June 1, 2022, you must apply for renewal under NMPA’s current standards, including updated classification catalog review and potentially a new CER. Choose the full NMPA renewal pathway with a gap analysis to identify what new documentation is needed.
If your device is new to the China market and falls within the expanded clinical exemption catalog, you can skip China-specific trials and file a registration dossier with a non-clinical evidence package. Choose the NMPA streamlined registration pathway via the e-Registration system, targeting a 60–90 working day review.
If your device is a novel Class III product with no predicate in China, you must follow NMPA’s innovation device pathway (创新医疗器械, chuàngxīn yīliáo qìxiè) which includes early consultation, priority review, and potentially conditional approval with post-market study requirements. Choose the innovation device pathway if you can demonstrate significant clinical advantage over existing alternatives.
3 Pitfalls When Navigating the SFDA-to-NMPA Transition
Timeline of China’s Medical Device Regulatory Evolution
The transition from SFDA to NMPA did not happen overnight. Understanding the timeline helps foreign manufacturers contextualize which regulations apply to their specific submission date.
- 2003: SFDA established, consolidating drug and device oversight. First Medical Device Regulation (State Council Decree No. 276) takes effect.
- 2013: SFDA renamed to CFDA. Provincial FDA offices gain authority over Class I registrations. Clinical trial requirements tightened.
- 2014: Revised Medical Device Regulation (State Council Decree No. 650) introduces risk-based classification and expands the exemption catalog to ~300 device types.
- 2017: China joins IMDRF as a founding member. Pilot programs begin for accepting overseas clinical data.
- 2018 (March): CFDA dissolved. NMPA established under SAMR. Food safety separated from medical products regulation.
- 2021: New classification catalog released with 2,069 categories, effective June 2022. Software classifications clarified.
- 2022: e-Registration portal launched. MDSAP audit recognition formalized. Transition period for legacy SFDA certificates ends December 31, 2024.
- 2023–2024: NMPA begins unannounced GMP audits for foreign manufacturers. Innovation device pathway usage increases by 35% year-over-year.
This timeline underscores a key reality: the regulatory environment is still evolving. Manufacturers who entered under SFDA rules may face different requirements now, and staying current requires active monitoring of NMPA notices and catalog updates.
NEXT STEPS
Navigating the shift from SFDA to NMPA requires both historical knowledge and current procedural expertise. Here are three concrete actions to take now:
- Audit your device’s classification. Check whether your device’s SFDA-era classification code maps correctly to NMPA’s 2021 catalog. If you are unsure, use our China Medical Device Classification Guide to identify the correct code and any reclassification risk.
- Assess your clinical data strategy. Determine whether your overseas clinical data qualifies for NMPA acceptance under the current Clinical Evaluation Report pathway. Read our China Clinical Trial Requirements for Medical Devices article to evaluate if you can avoid a full China trial.
- Engage a local regulatory partner. NMPA submissions require a Chinese legal entity (agent) with a valid business license. If you do not have a China entity, review our guide on Medical Device Registration in China for Foreign Manufacturers to find a qualified agent and avoid common agent-related pitfalls.
— China Gateway 360 —
Remote China market entry support, built around execution.
